<< Back To Search

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06066359
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of drugs that target the cancer cells more effectively.
  • Patients will receive the treatment in a controlled environment, allowing researchers to monitor its effects closely.
  • This study aims to determine how well the combination therapy works compared to standard treatments.
  • Participants will be closely observed for any side effects and overall health improvements.
  • The study includes a diverse group of patients to ensure the findings are applicable to a wide range of individuals.
Overall, this study is significant because it seeks to enhance the effectiveness of existing treatments and provide new options for patients. By focusing on a combination of therapies, researchers hope to improve survival rates and quality of life for those affected by this condition.
Third Opinion AI Generated Synopsis

Trial Summary
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: